[HTML][HTML] SARS-CoV-2 Omicron variant: recent progress and future perspectives
Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Immunological memory is the basis of protective immunity provided by vaccines and
previous infections. Immunological memory can develop from multiple branches of the …
previous infections. Immunological memory can develop from multiple branches of the …
Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron
A Fourth Dose of mRNA Vaccine in Health Care Workers Health care workers in Israel were
given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant …
given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant …
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4 …
SAC Clemens, L Weckx, R Clemens, AVA Mendes… - The Lancet, 2022 - thelancet.com
Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has
been widely used in a two-dose schedule. We assessed whether a third dose of the …
been widely used in a two-dose schedule. We assessed whether a third dose of the …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
Homologous and heterologous Covid-19 booster vaccinations
RL Atmar, KE Lyke, ME Deming… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective …
have received emergency use authorization in the United States are highly effective …
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet, 2022 - thelancet.com
Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
COVID-19 vaccination: The road ahead
DM Altmann, RJ Boyton - Science, 2022 - science.org
A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge
role in efforts to bring the COVID-19 pandemic under control, even though inequitable …
role in efforts to bring the COVID-19 pandemic under control, even though inequitable …
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
Background With the surge of new SARS-CoV-2 variants, countries have begun offering
COVID-19 vaccine booster doses to high-risk groups and, more recently, to the adult …
COVID-19 vaccine booster doses to high-risk groups and, more recently, to the adult …